The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder

被引:1
作者
Bartova, Lucie [1 ,2 ]
Fugger, Gernot [1 ,2 ]
Dold, Markus [1 ]
Kautzky, Alexander [1 ]
Swoboda, Marleen Margret Mignon [1 ]
Rujescu, Dan [1 ]
Zohar, Joseph [3 ]
Souery, Daniel [4 ,5 ]
Mendlewicz, Julien [4 ]
Montgomery, Stuart [6 ]
Fabbri, Chiara [2 ,7 ]
Serretti, Alessandro [2 ]
Kasper, Siegfried [1 ,8 ]
机构
[1] Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria
[2] Univ Bologna, Dept Biomed & NeuroMotor Sci, Bologna, Italy
[3] Chaim Sheba Med Ctr, Psychiat Div, Tel Hashomer, Israel
[4] Free Univ Brussels, Sch Med, Brussels, Belgium
[5] Psy Pluriel European Ctr Psychol Med, Brussels, Belgium
[6] Univ London, Imperial Coll Sch Med, London, England
[7] Kings Coll London, Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England
[8] Med Univ Vienna, Ctr Brain Res, Spitalgasse 4, A-1090 Vienna, Austria
关键词
Antidepressant treatment; aripiprazole; augmentation; major depressive disorder; quetiapine; second-generation antipsychotics; POSTTRAUMATIC-STRESS-DISORDER; TREATMENT-RESISTANT; PHARMACOLOGICAL-TREATMENT; ATYPICAL ANTIPSYCHOTICS; FUMARATE MONOTHERAPY; BIPOLAR DEPRESSION; DOUBLE-BLIND; EFFICACY; THERAPY; SCALE;
D O I
10.1093/ijnp/pyab066
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Augmentation with second-generation antipsychotics (SGAs) represents an evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient response to the first-line antidepressant (AD) treatment in major depressive disorder (MDD). Comparative evidence regarding efficacy and prescription preferences of the individual SGAs is scarce. Methods In the scope of this European, multi-site, naturalistic cross-sectional investigation with retrospective assessment of treatment outcome, we compared sociodemographic and clinical characteristics of 187 MDD patients receiving either quetiapine (n = 150) or aripiprazole (n = 37) as augmentation of their first-line AD psychopharmacotherapy. Results Comorbid posttraumatic stress disorder and diabetes were significantly associated with aripiprazole augmentation in our primary and post-hoc binary logistic regression analyses. Furthermore, we identified an association between aripiprazole co-administration and the presence of additional psychotic features, higher rates of AD combination treatment, and a longer duration of psychiatric hospitalizations during the lifetime, which, however, lost significance after correcting for multiple comparisons. Regarding treatment outcome, we found a trend of higher response rates and greater reductions in severity of depressive symptoms in MDD patients dispensed quetiapine. Conclusions Factors associated with a more chronic and severe profile of MDD seem to encourage clinicians to choose aripiprazole over quetiapine, that was, however, administered in the majority of our MDD patients, which might reflect the current approval situation allowing to prescribe exclusively quetiapine as on-label augmentation in MDD in Europe. Given the retrospective assessment of treatment response, the markedly smaller proportion of patients receiving aripiprazole augmentation generally showing an unfavorable disease profile, and the partially heterogeneous statistical robustness of our findings, further studies are required to elaborate on our observation and to generate unambiguous recommendations regarding the choice of first-line SGA augmentation in MDD.
引用
收藏
页码:118 / 127
页数:10
相关论文
共 50 条
[1]  
[Anonymous], 1997, SKID. Strukturiertes klinisches Interview fur DSM-IV, DOI DOI 10.1026//0084-5345.28.1.68
[2]  
Bahji A, 2020, J AFFECT DISORDERS, V269, P154, DOI 10.1016/j.jad.2020.03.030
[3]   Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis [J].
Bak, Maarten ;
Fransen, Annemarie ;
Janssen, Jouke ;
van Os, Jim ;
Drukker, Marjan .
PLOS ONE, 2014, 9 (04)
[4]   Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice [J].
Bartova, Lucie ;
Dold, Markus ;
Kautzky, Alexander ;
Fabbri, Chiara ;
Spies, Marie ;
Serretti, Alessandro ;
Souery, Daniel ;
Mendlewicz, Julien ;
Zohar, Joseph ;
Montgomery, Stuart ;
Schosser, Alexandra ;
Kasper, Siegfried .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, 20 (06) :427-448
[5]   Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines [J].
Bauer, Michael ;
Severus, Emanuel ;
Moller, Hans-Jurgen ;
Young, Allan H. .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2017, 21 (03) :166-176
[6]   Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation [J].
Bayes, A. J. ;
Parker, G. B. .
ACTA PSYCHIATRICA SCANDINAVICA, 2018, 137 (06) :459-471
[7]   Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review [J].
Britnell, Sara R. ;
Jackson, Anna D. ;
Brown, Jamie N. ;
Capehart, Bruce P. .
CLINICAL NEUROPHARMACOLOGY, 2017, 40 (06) :273-278
[8]   Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression [J].
Cantu, Filippo ;
Ciappolino, Valentina ;
Enrico, Paolo ;
Moltrasio, Chiara ;
Delvecchio, Giuseppe ;
Brambilla, Paolo .
JOURNAL OF AFFECTIVE DISORDERS, 2021, 280 :45-53
[9]   If at First You Don't Succeed A Review of the Evidence for Antidepressant Augmentation, Combination and Switching Strategies [J].
Connolly, K. Ryan ;
Thase, Michael E. .
DRUGS, 2011, 71 (01) :43-64
[10]   Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability [J].
Costa, Gabriela de Moraes ;
Zanatta, Fabricio Batistin ;
Ziegelmann, Patricia Klarmann ;
Soares Barros, Alcina Juliana ;
Mello, Carlos Fernando .
JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 130 :412-420